Transaction For the three-month period ended September 30, CONSOLIDATED Change (BAHT'000) 2019 2018 Amount % Interest income 4,696,115 4,200,604 495,511 11.8 Interest expenses 1,469,129 1,289,834 179,295 13.9
performance and financial position for the third quarter and nine-month ended September 30, 2019 with those of 2018. This report discusses principal changes in the reviewed consolidated financial statements
. The transaction size is equivalent to 98.67 percent of the net tangible assets (NTA) of the Company as appeared in the reviewed consolidated financial statement of the Company ending June 30, 2019, and
Acquisition of Assets of DOD Biotech Public Company Limited regarding the Acquisition of Land and Establishment of Subsidiary, which is Class 2 Transaction (Schedule 1) DOD Biotech Public Company Limited ( the
a connected person of the Company. The transaction size is equivalent to 222.36 percent of the NTA of the Company as appeared in the Company’s audited consolidated financial statements for the period
Ventures Public Company Limited for year ended December 31, 2017 We are pleased to submit: 1. Consolidated and Company only Annual Audited Financial Statements for the year ended December 31, 2017 (a copy in
incurred from deferred tax. This extra transaction was included in year ended 2017 financial statement for the net amount of THB 24 million. Revenue from Hospital Operations Revenue from hospital operations
ENDED MARCH 31, 2019 1. Analysis of operation results for Firs quarter of 2019 in compar ison with those for the same quarter of 2018 (from the consolidated financial statements) Items First quarter of
, 2018 1. Analysis of operation results for the third quar ter of 2018 in compar ison with those for the same quar ter of 2017 (from the consolidated financial statements) Items Third quarter of 2018 Third